Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769141 | 0.84 | MEN1 (0.47) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL2061274 | 0.80 | MAPT (0.54) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL6289865 | 0.78 | HTT (0.57) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL109470 | 0.78 | KMT2A (0.67) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL5123753 | 0.78 | CXCR2 (0.48) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL17105681 | 0.77 | CXCR2 (0.49) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL29208565 | 0.77 | CXCR1 (0.56) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL2470932 | 0.77 | KAT2B (0.52) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 | |
| SCHEMBL11477126 | 0.76 | MAPT (0.54) | ALDH1A1KMT2AMEN1HDAC6POLB | |
| SCHEMBL9649749 | 0.75 | MAPT (0.52) | ALDH1A1CXCR2CXCR1KCNMA1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | disclosed |
| CN-1492872-A | Tricyclic quinolinones and tricyclic quinolines as androgen receptor modulator compounds | ���ʵ�ҩƷ��˾ | 2004-04-28 | — | — | CN | disclosed |
| EP-1368357-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC, | 2003-10-02 | — | — | US | disclosed |
| CN-1391576-A | Androgen receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2003-01-15 | — | — | CN | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| US-6462038-B1 | SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS | LIGAND PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001016139-A9 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002068427-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1212330-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016139-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | ALDH1A1 1492/4885CXCR2 1734/4885CXCR1 1792/4885 |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | ALDH1A1 1492/4885CXCR2 1734/4885CXCR1 1792/4885 |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | ALDH1A1 2701/4885CXCR2 2446/4885CXCR1 1084/4885 |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | ALDH1A1 2490/4885CXCR2 2562/4885CXCR1 1339/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | ALDH1A1 2490/4885CXCR2 2562/4885CXCR1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.